Published in Clin Exp Pharmacol Physiol on July 24, 1975
Bioengineered human myobundles mimic clinical responses of skeletal muscle to drugs. Elife (2015) 1.10
Is malignant hyperpyrexia muscle denervated? J Neurol Neurosurg Psychiatry (1977) 0.75
A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology (1994) 3.23
The use of equilibrium-density-gradient methods for the preparation and characterization of blood-group-specific glycoproteins. Biochem J (1970) 2.98
Inheritance of malignant hyperpyrexia. Lancet (1972) 2.33
Improving the quality of antibiotic prescription patterns in general practice. The role of educational intervention. Med J Aust (1994) 2.02
Biochemical basis of malignant hyperpyrexia. Br Med J (1974) 2.01
Biochemical changes in malignant hyperpyrexia. Lancet (1970) 1.90
Myopathy and malignant hyperpyrexia. Lancet (1970) 1.87
Dantrolene and "ecstasy". Med J Aust (1997) 1.87
Changing antibiotic prescribing by educational marketing. Med J Aust (1989) 1.70
Arrhythmias and late sudden death after myocardial infarction. Lancet (1968) 1.68
Identification of susceptibility to malignant hyperpyrexia. Br Med J (1974) 1.66
Sources of calcium for contraction of guinea-pig isolated tracheal smooth muscle. Clin Exp Pharmacol Physiol (1981) 1.57
Procaine in malignant hyperpyrexia. Br Med J (1972) 1.49
Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs. Med J Aust (1996) 1.41
Malignant hyperpyrexia and sudden infant death. Lancet (1982) 1.36
Heat stroke and malignant hyperpyrexia. Med J Aust (1982) 1.36
The action of prazosin in human vascular preparations. Arch Int Pharmacodyn Ther (1978) 1.26
Rhabdomyolysis and malignant hyperpyrexia. Br Med J (Clin Res Ed) (1984) 1.22
Central-core disease and malignant hyperpyrexia. Br Med J (1973) 1.17
Etiology and pathophysiology of malignant hyperthermia. Int Anesthesiol Clin (1979) 1.14
The metabolism of arachidonic acid in the isolated tracheal and lung strip preparations of guinea-pigs. Lung (1980) 1.13
From knowledge to action: improving drug prescribing. Med J Aust (1996) 1.05
Anaphylaxis in guinea-pig peripheral airways in vitro. Eur J Pharmacol (1979) 1.05
Anesthetic-induced malignant hyperpyrexia in children. J Pediatr (1973) 1.04
A human arterial preparation for studying the effects of vasoactive agents. Circ Res (1978) 1.01
Heterogeneity of post-junctional alpha-adrenoceptors in human vascular smooth muscle. Arch Int Pharmacodyn Ther (1981) 0.99
The effect of calcium channel antagonists and BAY K 8644 on calcium fluxes of malignant hyperpyrexia-susceptible muscle. Int J Biochem (1993) 0.97
In vitro differences between human arteries and veins in their responses to hydralazine. J Pharmacol Exp Ther (1981) 0.96
Pharmaceutical advertisements in Australian medical publications--have they improved? Med J Aust (1995) 0.95
The interaction of concanavalin A with blood-group-substance glycoproteins from human secretions. Biochem J (1971) 0.95
Density gradient studies of A, B, H and Lea blood group specific glycoproteins. Clin Chim Acta (1970) 0.95
A controlled trial of long-term treatment with anticoagulants after myocardial infarction in 412 male patients. Med J Aust (1967) 0.94
Elimination of enoxacin in renal disease. Clin Pharmacol Ther (1987) 0.93
Prescriber guidelines improve initiation of anticoagulation. Med J Aust (1995) 0.91
The effects of platelet-derived contractile agents on human digital arteries. Clin Sci (Lond) (1984) 0.91
Herbal preparations--to regulate or not to regulate? Med J Aust (1989) 0.90
Educational antibiotic advertising. Med J Aust (1986) 0.89
Suxamethonium chloride and malignant hyperpyrexia. Br J Anaesth (1986) 0.88
Secretor status in asthma and hay fever. J Med Genet (1968) 0.87
Inositol 1,4,5-trisphosphate phosphatase deficiency and malignant hyperpyrexia in swine. Lancet (1989) 0.87
Studies on normal human skeletal muscle in relation to the pathopharmacology of malignant hyperpyrexia. Clin Exp Pharmacol Physiol (1977) 0.87
Neuronally released norepinephrine does not preferentially activate postjunctional alpha 1-adrenoceptors in human blood vessels in vitro. Circ Res (1985) 0.87
A study of the contractility, biochemistry and morphology of an isolated preparation of human skeletal muscle. Clin Sci Mol Med (1977) 0.86
The ABO system in milk and saliva. Australas Ann Med (1967) 0.86
Problems with herbal medicines. Med J Aust (1987) 0.84
A comparison of the effects of sodium thiocyanate and dantrolene sodium on a mammalian isolated skeletal muscle. Br J Pharmacol (1977) 0.84
Molecular cloning of the cDNA encoding human skeletal muscle triadin and its localisation to chromosome 6q22-6q23. Eur J Biochem (1995) 0.84
Effects of anaesthetics on guineapig tracheal smooth muscle. Br J Anaesth (1980) 0.84
Are neuronal uptake mechanisms responsible for the difference in sensitivity to noradrenaline between human arteries and veins? Clin Exp Pharmacol Physiol (1980) 0.83
ABO blood group, secretor status and gastric secretion. Australas Ann Med (1966) 0.83
Pharmacological comparison of human isolated digital arteries and metacarpal veins. Clin Exp Pharmacol Physiol (1982) 0.83
The effects of chlorbutol on skeletal muscle sarcoplasmic reticulum function in porcine malignant hyperpyrexia. Int J Biochem (1987) 0.82
Interaction between platelet-released serotonin and thromboxane A2 on human digital arteries. Clin Exp Pharmacol Physiol (1986) 0.82
Intra-dose variation in plasma protein binding of sodium valproate in epileptic patients. Br J Clin Pharmacol (1982) 0.82
Heterogeneity of human vascular pre- and post-synaptic alpha-adrenoceptors. Clin Sci (Lond) (1981) 0.82
Are the pre- and postsynaptic alpha-adrenoceptors in human vascular smooth muscle atypical? J Cardiovasc Pharmacol (1982) 0.82
The pathopharmacology of malignant hyperpyrexia. Pharmacol Ther (1980) 0.82
Differences between rat and guinea pig aorta in postreceptor mechanisms of alpha 1-adrenoceptors. J Cardiovasc Pharmacol (1991) 0.81
Calcium currents and asymmetric charge movement in malignant hyperpyrexia. Muscle Nerve (1989) 0.81
Effects of the beta-receptor antagonists propranolol, oxprenolol and labetalol on human vascular smooth-muscle contraction. Clin Sci Mol Med (1978) 0.81
Screening for malignant hyperpyrexia. Br J Anaesth (1977) 0.81
Site of the muscle cell abnormality in swine susceptible to malignant hyperpyrexia. Br J Anaesth (1980) 0.81
Sufentanil and alfentanil cause vasorelaxation by mechanisms independent of the endothelium. Clin Exp Pharmacol Physiol (1993) 0.80
Antagonism by nifedipine of alpha-1 and alpha-2 adrenoceptor-mediated responses of human digital arteries. J Pharmacol Exp Ther (1986) 0.80
Malignant hyperpyrexia in Australia and New Zealand. Med J Aust (1973) 0.80
Identification of susceptibility to malignant hyperpyrexia in swine. Br J Anaesth (1979) 0.80
Drug interactions in cat isolated tracheal smooth muscle. Clin Exp Pharmacol Physiol (1979) 0.79
Promoting and advertising therapeutic goods. Trade Practices Commission report on self-regulation. Med J Aust (1992) 0.79
The effect of histamine on cyclic AMP levels in guinea-pig tracheal smooth muscle. Eur J Pharmacol (1980) 0.79
Serum blood group substances and ABO haemolytic disease. Br J Haematol (1969) 0.79
The effect of prazosin of pre- and post-synaptic alpha-receptors in the pithed rat. Clin Exp Pharmacol Physiol (1979) 0.78
Unbound phenytoin plasma concentrations in patients comedicated with sodium valproate--the predictive value of plasma albumin concentration. Br J Clin Pharmacol (1989) 0.78
Exclusion of defects in the skeletal muscle specific regions of the DHPR alpha 1 subunit as frequent causes of malignant hyperthermia. J Med Genet (1995) 0.78
Smooth muscle contracture in malignant hyperpyrexia. Br J Anaesth (1980) 0.78
Letter: Myopathies and malignant hyperpyrexia. Br Med J (1974) 0.78
The effect of azumolene on hypercontractility and sarcoplasmic reticulum Ca(2+)-dependent ATPase activity of malignant hyperpyrexia-susceptible porcine skeletal muscle. Clin Exp Pharmacol Physiol (1991) 0.78
Intracellular Ca2+ and contractile responses to alpha 1-adrenoceptor subtype activation in rat aortic vascular smooth muscle. Eur J Pharmacol (1997) 0.78
Prejunctional beta-adrenoceptors in human digital arteries. Eur J Pharmacol (1982) 0.78
Temperature dependence of muscle function in malignant hyperpyrexia-susceptible swine. Br J Anaesth (1981) 0.78
Facilitatory prejunctional beta-adrenoceptors in human arteries and veins. Gen Pharmacol (1983) 0.78
Effect of diltiazem and dantrolene on the contractility of isolated malignant hyperpyrexia-susceptible porcine skeletal muscle. Br J Anaesth (1989) 0.78
Potentiation of human vascular smooth muscle contraction by angiotensin. J Cardiovasc Pharmacol (1980) 0.78
Drug treatment of malignant hyperpyrexia. Anaesth Intensive Care (1977) 0.78
Pharmacological comparison of isolated human cerebral and digital arteries. Stroke (1980) 0.77
Plasma concentrations of unbound valproate and the management of epilepsy. Aust N Z J Med (1987) 0.77
Detection and partial purification of inositol 1,4,5-trisphosphate 3-kinase from porcine skeletal muscle. Cell Signal (1994) 0.77
Drug advertising. Med J Aust (1986) 0.77
Alpha adrenoceptor activation and postreceptor contractile mechanisms in the human digital artery. J Pharmacol Exp Ther (1990) 0.77
Effects of fentanyl on the rat aorta are mediated by alpha-adrenoceptors rather than by the endothelium. Br J Anaesth (1993) 0.77
Techniques for testing isolated blood vessels. Gen Pharmacol (1983) 0.77
Drug advertising. Med J Aust (1989) 0.77
Responses of human arterial muscle to stable vasoactive substances released from human platelets by collagen and heat aggregated IgG. Clin Exp Pharmacol Physiol (1984) 0.77
Interaction of chlorpromazine with bile. Clin Chem (1971) 0.77
The effects of imidazole on contractility and cyclic AMP levels of guinea-pig tracheal smooth muscle. Clin Exp Pharmacol Physiol (1982) 0.77
Effect of diltiazem, verapamil and dantrolene on the contractility of isolated malignant hyperpyrexia-susceptible human skeletal muscle. Clin Exp Pharmacol Physiol (1989) 0.77
Reduced responses to noradrenaline of isolated digital arteries from hypertensives. Clin Exp Pharmacol Physiol (1981) 0.76